Boston Scientific Corporation (BSX) Stock Price & How to Invest

Boston Scientific Corporation is a Marlborough, Massachusetts-based medical device company that develops, manufactures, and markets minimally invasive devices used in interventional cardiology, electrophysiology, structural heart, peripheral interventions, endoscopy, urology, neuromodulation, and cardiac rhythm management. It reports through two broad segments: Cardiovascular, which houses the fast-growing electrophysiology business (led by the Farapulse pulsed field ablation system) and the Watchman left-atrial-appendage closure franchise, and MedSurg, which spans endoscopy, urology, and neuromodulation. The company sells into hospitals and physicians across roughly 130 countries and competes at the leading edge of catheter-based and device-based procedures that substitute for more invasive surgery.

Full-year 2025 revenue reached roughly $20 billion, with the Cardiovascular segment delivering about 21-22% organic growth on the strength of Farapulse (which launched in the United States in early 2024) and Watchman. Boston Scientific has built its current profile through both organic innovation and an active acquisition program, and management has guided full-year 2026 organic growth to roughly 6.5% to 8% with adjusted EPS of about $3.34 to $3.41. The investment picture centers on whether the company can keep compounding at high-single to low-double-digit rates as its newest products mature, while defending share against much larger diversified rivals in a market where clinical trial data, physician training, and reimbursement determine winners.

The most immediate concern flagged with 2026 guidance was unanticipated headwinds in electrophysiology, Watchman, and urology, which prompted management to frame organic growth guidance of 6.5% to 8%, below the pace of recent years and a signal that the newest franchises may be decelerating from peak growth rates. Competition is intensifying as Medtronic and Johnson and Johnson scale their own pulsed field ablation systems, which could erode Boston Scientific's early PFA share and pressure pricing. The stock has historically carried a premium valuation, so any slowdown in the growth narrative can trigger outsized share-price reactions, as seen in a sharp post-earnings selloff. Foreign exchange swings, hospital capital-spending cycles, product-recall or safety-signal risk inherent to implantable devices, and reimbursement or regulatory changes each add uncertainty. Integration risk from the company's ongoing acquisition strategy is a further variable that can affect margins and management focus.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Boston Scientific Corporation's investor relations page or your broker.

• Revenue (TTM): ~$20.6 billion
• Revenue (FY 2025): ~$20 billion
• Q1 2026 Revenue: ~$5.2 billion (+11.6% YoY reported, ~9.4% organic)
• Adjusted EPS Guidance (FY 2026): ~$3.34 to $3.41 (9% to 11% growth)
• Market Cap: ~$65 billion
• P/E Ratio (trailing): ~18x (forward ~13x)

Boston Scientific's trailing P/E of roughly 18x sits well below the peer-group average of roughly 34x cited by valuation trackers, a reversal from the sustained premium multiple the stock carried during its high-growth phase. The compression followed a steep share-price decline over the trailing year that coincided with a downward revision to organic growth guidance and disappointing signals in electrophysiology, Watchman, and urology. Net profit margin runs near 17%, and full-year 2026 adjusted EPS growth is guided to 9% to 11%, so the debate is whether the lower multiple reflects fair concern about decelerating growth or an over-correction relative to the franchise's still-double-digit earnings trajectory.

There are three common ways to get BSX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so BSX sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where BSX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Boston Scientific today is a double-digit-growth medical device franchise generating roughly $20.6 billion in trailing-twelve-month revenue, with Farapulse and Watchman as the core drivers and the central tension being whether that premium growth can sustain against slowing electrophysiology momentum and a rich starting valuation.

Whether BSX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is BSX a buy?, and where the stock could go from here in the BSX stock forecast.

For income investors, whether BSX pays a dividend and how the payout looks is covered in does BSX pay a dividend?